Table 1 Anthropometry, clinical characteristics and cardiovascular risk factors at baseline
Variable | Sample (n = 59) | AT group (n = 19) | LL-RT group (n = 19) | HL-RT group (n = 21) | p |
|---|---|---|---|---|---|
Age (years) | 61 (8) | 61 (9) | 61 (7) | 62 (8) | 0.910 |
Sex [males, (%)] | 44 (75) | 14 (74) | 15 (79) | 15 (71) | 0.931 |
Anthropometry | |||||
Height (cm) | 172.1 (8.4) | 170.4 (8.8) | 172.8 (8.6) | 172.9 (7.9) | 0.582 |
Weight (kg) | 85.47 (15.43) | 90.94 (19.04) | 81.46 (13.37) | 84.15 (12.56) | 0.148 |
Clinical data | |||||
LVEF (%) | 53 (9) | 50 (45,60) | 55 (50, 60) | 50 (45,58) | 0.454 |
Time from clinical event to inclusion in CR (months) | 2.0 (1.5, 3.0) | 2.0 (2.0,2.5) | 2.5 (1.5, 3.0) | 2.0 (1.5, 2.8) | 0.832 |
Myocardial infarction, f (%) | |||||
NSTEMI | 25 (42) | 9 (47) | 8 (42) | 8 (38) | 0.947 |
STEMI | 24 (41) | 7 (37) | 7 (37) | 10 (48) | |
Unstable AP/PCI | 10 (17) | 3 (16) | 4 (21) | 3 (14) | |
Comorbidities and risk factors, f (%) | |||||
Arterial hypertension | 41 (70) | 15 (79) | 11 (58) | 15 (71) | 0.383 |
Hyperlipidemia | 49 (83) | 16 (84) | 14 (74) | 19 (91) | 0.384 |
Diabetes | 9 (15) | 4 (21) | 3 (16) | 2 (10) | 0.602 |
Atrial fibrillation | 5 (9) | 4 (21) | 1 (5) | 0 (0) | 0.038 |
Thyroid disease | 5 (9) | 2 (11) | 2 (11) | 1 (5) | 0.727 |
Renal disease | 4 (7) | 0 (0) | 2 (11) | 2 (10) | 0.534 |
Smoking, f (%) | |||||
Non-smoker | 14 (24) | 3 (16) | 3 (16) | 8 (38) | 0.346 |
Ex-smoker | 35 (59) | 13 (68) | 11 (58) | 11 (52) | |
Current smoker | 10 (17) | 3 (16) | 5 (26) | 2 (10) | |
Pharmacological therapy, f (%) | |||||
ASA | 57 (97) | 17 (90) | 19 (100) | 21 (100) | 0.200 |
Beta blocker | 59 (100) | 19 (100) | 19 (100) | 21 (100) | 1.000 |
ACE inhibitor/ARB | 58 (98) | 19 (100) | 18 (95) | 21 (100) | 0.644 |
Statin/Ezetimibe | 59 (100) | 19 (100) | 19 (100) | 21 (100) | 1.000 |
Antiplatelets | 58 (98) | 18 (95) | 19 (100) | 21 (100) | 0.644 |
Anticoagulation | 5 (9) | 3 (16) | 1 (5) | 1 (5) | 0.509 |
Diuretic | 5 (9) | 4 (21) | 0 (0) | 1 (5) | 0.071 |